Skip to main content

Table 1 Characteristics of participants according to the provisional remission criteria

From: Concurrent validity of provisional remission criteria for gout: a dual-energy CT study

  All participants (n = 152) Provisional remission criteria fulfilled (n = 23) Provisional remission criteria not fulfilled (n = 129)
Age (years), mean (SD) 58 (11) 62 (11) 58 (11)
Male, n (%) 140 (92.1) 20 (97) 120 (93.0)
Race, n (%)
 White 98 (64.5) 16 (70) 82 (63.6)
 Non-white 54 (35.5) 7 (30) 47 (36.3)
Duration of gout (years), median (range) 12 (1–25) 10 (1–35) 12 (1–45)
Allopurinol daily dose, n (%)
 300 mg 124 (84.6) 21 (91) 103 (79.8)
 > 300 mg 28 (18.4) 2 (9) 26 (20.2)
Duration of allopurinol use (years), median (range) 2.9 (0.2–45) 3.3 (0.3–27) 2.8 (0.2–45)
Serum urate (< 0.36 mmol/L) 77 (50.7) 23 (100) 54 (41.9)
Tophus (absence) 104 (68.4) 23 (100) 81 (62.8)
Flares (none in the last 12 months) 70 (46.1) 23 (100) 47 (36.4)
Pain (due to gout, < 2) 104 (68.4) 23 (100) 81 (62.8)
Patient global assessment of gout activity (< 2) 84 (55.2) 23 (100) 61 (47.3)